PRA Health Sciences Inc (NASDAQ:PRAH) Receives $105.23 Consensus Target Price from Analysts

Share on StockTwits

PRA Health Sciences Inc (NASDAQ:PRAH) has been assigned a consensus recommendation of “Hold” from the fifteen brokerages that are presently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $105.23.

PRAH has been the topic of several analyst reports. Credit Suisse Group lifted their target price on shares of PRA Health Sciences from $113.00 to $116.00 and gave the stock an “outperform” rating in a research report on Friday, August 7th. UBS Group boosted their price objective on shares of PRA Health Sciences from $105.00 to $111.00 and gave the company a “neutral” rating in a research report on Monday, August 10th. Bank of America downgraded shares of PRA Health Sciences from a “neutral” rating to an “underperform” rating and set a $100.00 price objective on the stock. in a research report on Monday, August 10th. Mizuho boosted their price objective on shares of PRA Health Sciences from $92.00 to $108.00 and gave the company an “in-line” rating in a research report on Monday, August 10th. Finally, BofA Securities downgraded shares of PRA Health Sciences from a “buy” rating to an “underperform” rating and lowered their price objective for the company from $110.00 to $100.00 in a research report on Monday, August 10th.

In other PRA Health Sciences news, CFO Michael J. Bonello sold 2,052 shares of PRA Health Sciences stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $102.88, for a total value of $211,109.76. Following the completion of the sale, the chief financial officer now directly owns 21,276 shares in the company, valued at $2,188,874.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Christopher L. Gaenzle sold 1,364 shares of PRA Health Sciences stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $102.88, for a total transaction of $140,328.32. Following the completion of the sale, the chief accounting officer now owns 37,636 shares of the company’s stock, valued at $3,871,991.68. The disclosure for this sale can be found here. Insiders sold 9,489 shares of company stock valued at $976,228 over the last quarter. Corporate insiders own 1.30% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Fortis Advisors LLC acquired a new stake in shares of PRA Health Sciences in the first quarter worth $34,000. Citizens Financial Group Inc RI lifted its stake in shares of PRA Health Sciences by 753.2% in the second quarter. Citizens Financial Group Inc RI now owns 657 shares of the medical research company’s stock worth $64,000 after buying an additional 580 shares during the last quarter. Financial Management Professionals Inc. acquired a new stake in shares of PRA Health Sciences in the second quarter worth $99,000. Cullen Frost Bankers Inc. lifted its stake in shares of PRA Health Sciences by 406.8% in the second quarter. Cullen Frost Bankers Inc. now owns 1,120 shares of the medical research company’s stock worth $109,000 after buying an additional 899 shares during the last quarter. Finally, Tower Research Capital LLC TRC acquired a new stake in shares of PRA Health Sciences in the first quarter worth $164,000. Institutional investors and hedge funds own 96.69% of the company’s stock.

Shares of PRA Health Sciences stock traded up $0.72 during trading on Monday, hitting $105.83. The stock had a trading volume of 484,038 shares, compared to its average volume of 418,722. The stock has a 50 day simple moving average of $101.94 and a 200 day simple moving average of $95.54. The company has a market capitalization of $6.77 billion, a PE ratio of 32.46, a P/E/G ratio of 2.31 and a beta of 1.02. The company has a quick ratio of 0.98, a current ratio of 0.98 and a debt-to-equity ratio of 1.08. PRA Health Sciences has a 1 year low of $58.67 and a 1 year high of $113.32.

PRA Health Sciences (NASDAQ:PRAH) last released its earnings results on Thursday, August 6th. The medical research company reported $0.69 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.05. The business had revenue of $729.89 million for the quarter, compared to the consensus estimate of $716.12 million. PRA Health Sciences had a net margin of 6.86% and a return on equity of 25.01%. The firm’s quarterly revenue was down 4.4% compared to the same quarter last year. During the same period last year, the firm posted $1.22 earnings per share. As a group, equities analysts expect that PRA Health Sciences will post 3.71 earnings per share for the current fiscal year.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

See Also: What is a SEC Filing?

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply